The combination of bevacizumab/Avastin and erlotinib/Tarceva is relevant for the treatment of metastatic renal cell carcinoma: the role of a synonymous mutation of the EGFR receptor

Metastatic clear cell renal cell carcinomas (mRCC) over-express the vascular endothelial growth factor (VEGF). Hence, the anti-VEGF antibody bevacizumab/Avastin (BVZ) combined with interferon alpha (IFN) was approved for the treatment of mRCC. However, approval was lost in July 2016 due to the absen...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Theranostics
Hlavní autoři: Grépin, Renaud, Guyot, Mélanie, Dumond, Aurore, Durivault, Jérôme, Ambrosetti, Damien, Roussel, Jean-François, Dupré, Florence, Quintens, Hervé, Pagès, Gilles
Médium: Artigo
Jazyk:Inglês
Vydáno: Ivyspring International Publisher 2020
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6956821/
https://ncbi.nlm.nih.gov/pubmed/31938054
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.38346
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky